Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia

Annals of Surgical Oncology

Volumn 10, Issue 4, 2003, Pages 463-468

  Mohamed, Faheez ^a   Marchettini, Pierre ^a   Stuart, O Anthony ^a   Urano, M ^b   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Animal tumors; Hyperthermia; Intraperitoneal chemotherapy; Thermal enhancement

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; IRINOTECAN; MELPHALAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MEGADOSE; FIBROSARCOMA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IMMERSION; LOW DRUG DOSE; MOUSE; NONHUMAN; TEMPERATURE; TREATMENT OUTCOME; TUMOR MODEL; ANIMAL; C3H MOUSE; DRUG SCREENING;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROSARCOMA; HYPERTHERMIA, INDUCED; MELPHALAN; MICE; MICE, INBRED C3H; ORGANOPLATINUM COMPOUNDS; PACLITAXEL;

EID: 0042662540     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.08.006     Document Type: Article

References (38)

1. Engelhard R. Hyperthermia and drugs. Recent Results Cancer Res 1987;104:136-203.
2. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39:2264-8.
3. 4A in vivo. Anticancer Res 1982;2:359-64.
4. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;22:665-7.
5. Thigpen JT. Chemotherapy for advanced ovarian cancer. Overview of randomised trials. Semin Oncol 2000;27:11-6.
6. Cortes JE, Padzur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
7. Verweij J, Clavel M, Chevalier B, Paclitaxel (Taxol™) and docetaxel (Taxotere™). Not simply two of a kind. Ann Oncol 1994;5:495-505.
8. Barton JS, Vandivort DL, Heacock DH, Coffman JA, Trygg KA. Microtubule assembly kinetics. Changes with solution conditions. Biochem J 1987;247:505-11.
9. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999;15:225-36.
10. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996;23(1 Suppl 3):34-41.
11. Kondo T, Ueda K, Kano E. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Res 1995;15:83-6.
12. Rietbroek RC, van de Vaart PJ, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997;123:6-12.
13. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267-72.
14. Grindey GB, Broder GB, Hertel LW, et al. Antitumor activity of 2′, 2′-difluorodeoxycytidine (LY 188011). Proc Am Assoc Cancer Res 1986;27:296.
15. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′2′-difluoro-2′ deoxycytidine). Cancer Res 1990;50:4417-22.
16. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996;7:347-53.
17. Hui YF, Reitz J. Gemcitabine. A cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997;54:162-70.
18. Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(4 Suppl 11):3-10.
19. Van Bree C, Beumer C, Rodermond HM, Haveman J, Bakker PJM. Effectiveness of 2′,2′difluorodeoxycytidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 1999;15:549-56.
20. Urano M, Majima H, Miller R, Kahn J. Cytotoxic effect of 1,3 bis (2-chloroethyl)-N-nitrosourea at elevated temperatures: Arrhenius plot analysis and tumor response. Int J Hyperthermia 1991;7:499-510.
21. Urano M, Gerweck LE, Epstein R, Cunningham M, Suit HD. Response of spontaneous murine tumor to hyperthermia: factors which modify the thermal response in vivo. Radiat Res 1980;83: 312-22.
22. Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998;84:708-13.
23. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999;15:79-107.
24. Dahl O. Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity. In: Urano M, Douple E, eds. Hyperthermia and Oncology. Utrecht, The Netherlands: VSP, 1994:29.
25. Dumontet C, Bodin F, Michal Y. Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistance. Clin Cancer Res 1998;4:1563-6.
26. Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997;13: 525-33.
27. Othman, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001;62:208-12.
28. Cividalli A, Livdi E, Ceciarelli F, et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 2000;16: 61-71.
29. Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 1998;8:240-4.
30. Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/ hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993;24:129-38.
31. Katschinski DM, Robins HI. Hyperthermic modulation of SN-38 induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity. Int J Cancer 1999;80: 104-9.
32. Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxy-cytidine (gemcitabine) in cultured SW 1573 cells. Int J Cancer 1995;62:627-30.
33. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988;6: 1768-82.
34. Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 2002;18:307-15.
35. Lienard D, Eggermont AM, Kroon BBR, Koops HS, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998;14:202-9.
36. Koops HS. Eggermont AM, Lienard D, et al. Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol 1998;14:210-4.
37. Knox JD, Mitchel REJ, Brown DL. Effects of hyperthermia on microtubule organization and cytolytic activity of murine cytotoxic T lymphocytes. Expl Cell Res 1991;194:275-83.
38. Clark BD, Brown IR. Altered expression of a heat shock protein in the mammalian nervous system in the presence of agents which affect microtubule stability. Neurochem Res 1987;12:819-23.